Get the Stockscreener App
38.65
1.90%
0.72
After Hours:
38.65
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Q4 Earnings: CEO and CFO Set to Unveil Full Year Performance Metrics - StockTitan
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking - Simply Wall St
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight - The Globe and Mail
Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha
Supernus wins FDA approval for Parkinson’s pump on fourth try - Yahoo Finance
US FDA approves Supernus' drug-device combination for Parkinson's disease - MSN
Top Supernus Executive Offloads Significant Stock Holdings! - TipRanks
Supernus Pharmaceuticals exec sells shares worth $376,236 - MSN
Supernus Pharmaceuticals exec sells shares worth $376,236 By Investing.com - Investing.com Canada
FDA nod at last for Supernus’ Parkinson’s infusion therapy - The Pharma Letter
Stifel maintains hold on Supernus, price target at $38 - MSN
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire
Supernus stock climbs 5% on FDA approval of Onapgo - MSN
Supernus Pharmaceuticals Inc [SUPN] Stock sold by Insider Bhatt Padmanabh P. for $0.1 million - Knox Daily
Supernus stock price target raised to $44 at TD Cowen - MSN
Supernus stock price target raised to $44 at TD Cowen By Investing.com - Investing.com Canada
Stifel maintains hold on Supernus, price target at $38 By Investing.com - Investing.com UK
Supernus stock surges on FDA approval By Investing.com - Investing.com Canada
U.S. FDA approves Supernus' drug-device combination for Parkinson's disease - Reuters
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease - MarketWatch
Supernus Pharmaceuticals Says Onapgo Approved by FDA for Parkinson's Disease - Marketscreener.com
FDA Approves Drug Pump for Parkinson's Disease - Newsmax
Supernus Announces FDA Approval of ONAPGO? (apomorphine hydrochloride) for Parkinson?s Disease - Marketscreener.com
SG Americas Securities LLC Takes $391,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
SG Americas Securities LLC Invests $391,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - ETF Daily News
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.7%Here's Why - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 700 Shares - MarketBeat
China Universal Asset Management Co. Ltd. Raises Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Pacer Advisors Inc. - MarketBeat
Supernus Pharmaceuticals exec sells $129,676 in stock By Investing.com - Investing.com Australia
Supernus Pharmaceuticals exec sells $129,676 in stock - Investing.com India
SUPN stock soars to 52-week high, hits $39.38 amid growth - MSN
(SUPN) Proactive Strategies - Stock Traders Daily
Supernus Announces Label Update for Non-Stimulant ADHD - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighShould You Buy? - MarketBeat
FDA approves Qelbree label update for ADHD treatment - Investing.com
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women - Marketscreener.com
FDA Approves Groundbreaking Label Update for Supernus ADHD Drug Qelbree - StockTitan
Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Purdue Pharma and owners to pay $7.4 billion in settlement of lawsuits over the toll of OxyContin - MSN
Wedge Capital Management L L P NC Invests $1.93 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. Enters into Lease Agreement for Approximately 136,016 Square Feet for its New Headquarters with Advent Key West, LLC - Marketscreener.com
Hennion & Walsh Asset Management Inc. Acquires 25,004 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Burney Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by JPMorgan Chase & Co. - Defense World
Schrödinger receives regulatory approval for Novartis collaboration - MSN
Despite the downward trend in earnings at Supernus Pharmaceuticals (NASDAQ:SUPN) the stock advances 3.1%, bringing five-year gains to 56% - Simply Wall St
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
SUPN (Supernus Pharmaceuticals) Intrinsic Value: DCF (FCF B - GuruFocus.com
2.34%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):